Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Communication | 3 | 2026 | 543 | 1.300 |
Why?
|
| Health Literacy | 3 | 2025 | 77 | 0.980 |
Why?
|
| Students, Medical | 2 | 2021 | 347 | 0.920 |
Why?
|
| Patient Participation | 1 | 2026 | 254 | 0.780 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 165 | 0.710 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2021 | 430 | 0.700 |
Why?
|
| Reading Frames | 1 | 2021 | 2 | 0.700 |
Why?
|
| Kidney Transplantation | 1 | 2026 | 558 | 0.660 |
Why?
|
| Gene Silencing | 1 | 2021 | 229 | 0.650 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 258 | 0.610 |
Why?
|
| Medically Uninsured | 1 | 2019 | 79 | 0.560 |
Why?
|
| Caregivers | 1 | 2024 | 598 | 0.540 |
Why?
|
| Mass Screening | 1 | 2024 | 822 | 0.540 |
Why?
|
| Mobile Health Units | 3 | 2025 | 24 | 0.540 |
Why?
|
| Health Services Accessibility | 2 | 2026 | 712 | 0.530 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2026 | 853 | 0.520 |
Why?
|
| Entropy | 1 | 2016 | 30 | 0.500 |
Why?
|
| Heart Diseases | 1 | 2021 | 499 | 0.500 |
Why?
|
| Epistasis, Genetic | 1 | 2016 | 96 | 0.490 |
Why?
|
| Electrocardiography | 1 | 2021 | 970 | 0.480 |
Why?
|
| Life Style | 1 | 2019 | 456 | 0.470 |
Why?
|
| Health Promotion | 1 | 2019 | 422 | 0.450 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 419 | 0.400 |
Why?
|
| Curriculum | 2 | 2025 | 798 | 0.290 |
Why?
|
| Cross-Sectional Studies | 3 | 2026 | 3829 | 0.270 |
Why?
|
| Tuberculosis | 3 | 2022 | 550 | 0.250 |
Why?
|
| Communication Barriers | 1 | 2026 | 47 | 0.230 |
Why?
|
| Strongyloides | 1 | 2025 | 22 | 0.230 |
Why?
|
| Strongyloidiasis | 1 | 2025 | 52 | 0.220 |
Why?
|
| Antitubercular Agents | 2 | 2018 | 275 | 0.220 |
Why?
|
| Pediatrics | 2 | 2025 | 1252 | 0.210 |
Why?
|
| Internship and Residency | 2 | 2025 | 1223 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2025 | 169 | 0.190 |
Why?
|
| Delphi Technique | 1 | 2024 | 283 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2026 | 730 | 0.180 |
Why?
|
| Isoniazid | 2 | 2022 | 69 | 0.180 |
Why?
|
| Humans | 13 | 2026 | 131163 | 0.170 |
Why?
|
| INDEL Mutation | 1 | 2021 | 93 | 0.170 |
Why?
|
| Latent Tuberculosis | 1 | 2022 | 75 | 0.160 |
Why?
|
| Genes, Bacterial | 1 | 2021 | 215 | 0.160 |
Why?
|
| Exercise Test | 1 | 2021 | 239 | 0.160 |
Why?
|
| Genome, Bacterial | 1 | 2021 | 200 | 0.160 |
Why?
|
| Adult | 4 | 2026 | 31282 | 0.160 |
Why?
|
| Self-Assessment | 1 | 2020 | 58 | 0.150 |
Why?
|
| 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase | 1 | 2018 | 1 | 0.150 |
Why?
|
| Faculty | 1 | 2020 | 99 | 0.140 |
Why?
|
| Language | 1 | 2021 | 219 | 0.140 |
Why?
|
| Male | 6 | 2026 | 64957 | 0.140 |
Why?
|
| Female | 7 | 2026 | 70963 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2018 | 237 | 0.140 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 644 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 4066 | 0.130 |
Why?
|
| Ethambutol | 1 | 2016 | 7 | 0.120 |
Why?
|
| Medicare | 1 | 2020 | 442 | 0.120 |
Why?
|
| Medicaid | 1 | 2019 | 268 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.110 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 317 | 0.110 |
Why?
|
| Middle Aged | 2 | 2026 | 28601 | 0.110 |
Why?
|
| Adolescent | 3 | 2025 | 20987 | 0.100 |
Why?
|
| Models, Genetic | 1 | 2016 | 749 | 0.100 |
Why?
|
| Child | 4 | 2025 | 26341 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1118 | 0.090 |
Why?
|
| United States | 4 | 2025 | 12072 | 0.090 |
Why?
|
| Diet | 1 | 2019 | 1121 | 0.090 |
Why?
|
| Parents | 1 | 2019 | 1128 | 0.080 |
Why?
|
| Aged | 2 | 2026 | 21025 | 0.080 |
Why?
|
| Antibodies, Helminth | 1 | 2025 | 131 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2025 | 787 | 0.050 |
Why?
|
| Mutation | 1 | 2016 | 6099 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 512 | 0.040 |
Why?
|
| Tuberculin Test | 1 | 2022 | 120 | 0.040 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2022 | 91 | 0.040 |
Why?
|
| Models, Organizational | 1 | 2020 | 43 | 0.040 |
Why?
|
| North Carolina | 1 | 2020 | 48 | 0.040 |
Why?
|
| Georgia | 1 | 2020 | 46 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 73 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 83 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 554 | 0.040 |
Why?
|
| Crystallography | 1 | 2018 | 39 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 2701 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 915 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 2018 | 105 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 172 | 0.030 |
Why?
|
| Health Policy | 1 | 2020 | 234 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2018 | 179 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2024 | 1050 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 978 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2020 | 407 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 1064 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2552 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2016 | 401 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2016 | 859 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1801 | 0.020 |
Why?
|
| Animals | 2 | 2025 | 33912 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 3686 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 11074 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 953 | 0.020 |
Why?
|
| Infant | 1 | 2025 | 13352 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2025 | 15110 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 18301 | 0.010 |
Why?
|